Welcome to our searchable resource and literature collection on safer supply and related topics.

Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.


Safer supply pilot programs provide prescribed doses of pharmaceutical alternatives to individuals accessing the unregulated drug supply and have been implemented to prevent overdose and reduce rel

Original research | 2023
Safer supply, Policy/Regulatory
Commentary | 2023
Parents/caregivers, Equity, Policy/Regulatory

Our objectives were to curate information about xylazine through social media from people who use drugs (PWUDs).

Original research | 2023
About PWUD, Illegal drugs

In early 2021, both Oregon and Washington fully (Oregon) or partially (Washington) decriminalized possession of small amounts of all drugs.

Original research | 2023
Decriminalization/legalization, Legal system/law enforcement, Policy/Regulatory

The Safer Bathroom project sought to address long-standing policy and practice gaps by developing a toolkit to improve bathroom overdose prevention and response.

Original research | 2023
Harm reduction, Overdose
Cours de formation | 2023
la douleur chronique, à propos des prescripteurs, les guides de pratique clinique
Training | 2023
Chronic pain, About prescribers, Clinical guidance
Webpage | 2023
Harm reduction, About PWUD, Parents/caregivers
Guide or handbook | 2022
Safer supply, About prescribers, Hesitancy of prescribers

We examined acceptability of and preferences for potential medications for treating methamphetamine use disorder (MUD) among people who use methamphetamine and examined how benefits and drawbacks o

Original research | 2023
Stimulants, Safer supply, About PWUD

A scoping review was undertaken to examine the impact of methamphetamine use on medications for opioid use disorder [MOUD] retention.

Scoping review | 2023
Stimulants, About PWUD, Substitution/OAT, Transitions in care/treatment

We conducted a qualitative study evaluating one opioid treatment program's experience, including benefits and challenges with implementing a methadone van, to inform future policy and clinical prac

Original research | 2023
Barriers and enablers, Substitution/OAT, About prescribers, About PWUD

We discuss major domains of xylazine’s harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine’s public health and policy context.

Lit review | 2023
About prescribers, Illegal drugs, Harm reduction, Clinical guidance

The COVID-19 pandemic led to an unprecedented relaxation of restrictions on take-home doses in opioid agonist treatment (OAT).

Lit review | 2023
Carries/take-home doses, Hesitancy of prescribers , Policy/Regulatory

Emerging literature suggests that healthcare workers also experience moral injury, particularly in the context of the ongoing COVID-19 pandemic.

Original research | 2023
About prescribers, Mental health, Workplace
Commentary | 2023
Overdose, Illegal drugs, Clinical guidance

In this study, we seek to evaluate the experiences of Black individuals with OUD in seeking treatment.

Original research | 2023
Equity, Substitution/OAT, Diversion, About PWUD

Refine Your Search